Trials / Not Yet Recruiting
Not Yet RecruitingNCT07230119
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 744 (estimated)
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zovaglutide dose 1 | administered subcutaneously (SC), Q4W |
| DRUG | Zovaglutide dose 2 | administered subcutaneously (SC), Q4W |
| DRUG | Placebo | administered subcutaneously (SC), Q4W |
Timeline
- Start date
- 2026-03-08
- Primary completion
- 2027-05-29
- Completion
- 2027-06-26
- First posted
- 2025-11-17
- Last updated
- 2025-12-23
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07230119. Inclusion in this directory is not an endorsement.